by Christian Hayden and Laura Farmer
The insightful 2026 Healthcare AI ROI Scorecard from Bessemer Venture Partners and Bain contains an apparent paradox for pharma. AI pilots are proliferating: the share of pharma use cases in pilot stage rose 11 percentage points over the past year. Scaled production, however, rose just 1 point. Meanwhile, the clearest returns are early in the value chain. Preclinical discovery delivered 3.4x realized ROI, versus 2.3x for clinical development and 2.6x for commercial.
The obvious read is that pharma should chase the highest near-term returns. At Opus, we see a second possibility: the pilot-to-production gap may be partly explained by the difficulty of measuring value on a useful timeline. If a team can’t put a defensible number on a tool’s value, it’s hard to justify scaling it.
Preclinical discovery may be the exception that proves the point. It leads pharma today in both AI adoption and realized ROI. Further downstream, it gets much harder to accurately attribute value: drug development unfolds over many years and outcomes have many causes, so the ultimate financial impact of an AI-assisted decision can arrive long after it was made.
Most of the highest-stakes AI applications don’t offer the luxury of a clean, near-term payoff. An AI tool that sharpens target selection, trial design, patient identification, competitive decision-making, or portfolio prioritization may create enormous value. But the biggest payoff may be terminating a weak program before an expensive late-stage trial, or identifying a promising asset that otherwise would have been deprioritized. Given the enormous cost of late-stage failure, even a modest improvement in the probability of making the right go/no-go decision could dwarf years of incremental productivity savings.
A similar challenge exists in pharma sales and marketing. AI can deliver readily measurable efficiency gains in content development and field force operations, but assessing its impact on HCP targeting, personalized engagement, and commercial strategy is more complicated. The important question isn’t just whether AI made commercial activities faster or cheaper, but whether it improved resource allocation, influenced prescribing behavior, or generated incremental revenue that wouldn’t otherwise have materialized.
In other words, some of AI’s most consequential impacts in pharma may take years to become visible. And even then, isolating AI’s contribution to the outcome can be difficult. Companies therefore need meaningful ways to assess value along the way. Beyond direct cost savings and productivity, pharma companies should ask of an AI application:
• Did it shorten the time to a decision?
• Did it allow the team to evaluate more options with the same resources?
• Did it surface risks or opportunities earlier?
• Did it lead to better decisions?
Answering that last question is, of course, easier said than done. A tool can make a team more certain… and more wrong. The test is retrospective: did AI-informed go/no-go calls outperform historical base rates, and did earlier risk flags actually predict later failures?
Ultimately, what matters is whether AI helps companies put capital and scientific resources behind the right development programs. That’s difficult to capture in a quarterly calculation, but in an industry where one better development decision can be worth billions, it’s a measure worth getting right.
It’s a question we’re spending more time on at Opus Strategy: how do you measure AI’s contribution rigorously enough to guide investment decisions without waiting years to find out whether those investments paid off? We’d be interested to hear how others in biopharma are approaching it.